^
+ Follow DR. BARNER Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226916
                    [Title] => First patient enrolled in stroke prevention trial
                    [Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned. 


PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.

The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 225183 [Title] => Analysis shows safety of post-stroke therapy [Summary] => Meta-analysis of nearly 340,000 post-stroke patients shows the superior safety of dipyridamole plus aspirin therapy.

The results of the analysis presented at the recent American Heart Association’s annual meeting, showed that the therapy was associated with the lowest bleeding risk compared with conventional dose and platelet therapies.

The meta-analysis included data from 50 clinical trials published from 1988 to 2002, with a total of 338,191 patients, to determine bleeding risks associated with antiplatelet agents.
[DatePublished] => 2003-10-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. BARNER
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226916
                    [Title] => First patient enrolled in stroke prevention trial
                    [Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned. 


PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.

The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 225183 [Title] => Analysis shows safety of post-stroke therapy [Summary] => Meta-analysis of nearly 340,000 post-stroke patients shows the superior safety of dipyridamole plus aspirin therapy.

The results of the analysis presented at the recent American Heart Association’s annual meeting, showed that the therapy was associated with the lowest bleeding risk compared with conventional dose and platelet therapies.

The meta-analysis included data from 50 clinical trials published from 1988 to 2002, with a total of 338,191 patients, to determine bleeding risks associated with antiplatelet agents.
[DatePublished] => 2003-10-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with